142.86 0.00 (0.00%)
After hours: 5:22PM EDT
|Bid||143.06 x 1000|
|Ask||143.16 x 800|
|Day's Range||142.78 - 145.42|
|52 Week Range||104.90 - 164.13|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||118.07|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||176.19|
IQVIA Holdings Inc. , will announce its third-quarter 2019 financial results before the market opens on Wednesday, October 30, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
Once again, top executives with ties to Triangle companies are walking away with millions of dollars in insider stock sales.
IQVIA™ (IQV) today announced the launch of Orchestrated Patient Engagement (OPE), a new cloud-based software as a service (SaaS) solution that helps close the gap between life sciences companies and patients. The OPE SaaS solution is powered by Belong.Life technology to allow life sciences customers to facilitate interactions and gain insights from patients who opt-in, assisting in the commercialization process.
IQVIA Consumer Health announces its unique global technology and analytics suite to support the self-care and wellness industry from product concept to consumer use
IQVIA's (IQV) latest launch is aimed at helping MedTech companies comply with the new European Union Medical Device Regulation, through extended capabilities.
IQVIA™ (IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE). This research helps confirm that clinical benefits seen for therapies in clinical trials were consistent with the benefits of those treatments within real world settings. RWE comprises dynamic data including assets such as EMR, hospital, pharmacy, and claims sources, as well as genomics, mobile health, and patient reported outcomes.
The first Enterprise Quality Management Solution in the industry with expanded capabilities for European Union Medical Device Regulation regulations and compliance
IQVIA Holdings (IQV) is likely to benefit from the evolving growth opportunities in the life sciences industry. A highly leveraged balance sheet remains a concern.
Wednesday's gain may not have been enough to carry the S&P 500 index all the way back above its pivotal 50-day moving average line, but the 1.08% rally was enough to get stocks to within striking distance of that feat.Source: Shutterstock General Electric (NYSE:GE) did much of the heavy lifting, gaining more than 5% after Citigroup suggested its turnaround effort "could be more significant" than the market presently appreciates. Meanwhile, Roku (NASDAQ:ROKU) may have made less of an overall impact, but still logged a bigger gain by rallying nearly 8% after D.A. Davidson analyst Tom Forte upped his target to $185 -- the highest on Wall Street.Despite the rising tide, however, not every name was a winner. American Eagle Outfitters (NYSE:AEO) tumbled more than 11% after reporting same-store sales growth of 2%, versus the 6% analysts were modeling.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Best Tech Stocks to Buy Right Now As for names worth a closer look as we move into the home stretch of the short trading week, however, take a look at stock charts of Iqvia Holdings (NYSE:IQV), Xilinx (NASDAQ:XLNX) and Norfolk Southern (NYSE:NSC). Here's why, and what may come next. Norfolk Southern (NSC)The past few weeks have been tough ones for railroad stocks. Norfolk Southern has been no exception.Since the middle of last month, things have seemingly changed. NSC stock appears to have found support -- or perhaps made support -- before matters got too far out of hand. While there's reason for optimism, there's also reason for concern. One more slip-up from here could crack a couple of different key floors and send Norfolk shares off the rails. * Click to EnlargeOne of those floors is $168.37, plotted in white on the daily chart. Shares have been unable and unwilling to move below that market since the middle of last month. * Zooming out to the weekly chart of NSC stock, it's clear there's another support line at work. The line that connects most, even if not all, the major lows since 2016 is once again being tested. * Should the two floors snap and let the bears continue on, there's not much historical precedent for the next-best landing spot. The most-likely level is December's bottom around $140. Iqvia Holdings (IQV)It's been anything but a straight-line effort, but Iqvia Holdings has been a surprisingly rewarding name over the past several years. Buying on the dip has been a savvy strategy' It still is.To that end, though some could and would argue that the lull witnessed since late June technically qualifies as a dip since it was stopped at an established technical floor, that may not be the case at all. One stumble could easily break that support level and send IQV stock to a better-established support level. And, the subtle clues suggest that's the more-likely outcome here. * Click to EnlargeThe make-or-break level on the daily chart is $150.63, marked in white in the graph. * On the weekly chart, however, the floor of interest is different. The line that connects the key lows since late December, marked in yellow, is being tested. * Should either or both floor fail to keep Iqvia propped up, the next most=likely support level is near $120. That's where the lower boundary of a trading range established in 2016 and 2017 lies, marked as a dashed blue line. * It's been relatively uneven, but it's difficult to say the daily chart's volume bars aren't more bearish than bullish. That is to say, the red lines are taller and more frequent than the green volume bars. Xilinx (XLNX)Finally, with just a quick glance, it seems Xilinx shares have sidestepped trouble. Finding the same floor they found in May, the pullback that started in late July has been halted as of last week. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off A closer look at the chart of XLNX stock, however, reveals shares may not be as risk-free as first thought. The stock is finding resistance at a place it can't afford to face resistance, and that could buy the bears just enough time to shore up their defensive line and force Xilinx to lose ground. One small stumble could get very big, very fast. * Click to EnlargeThe support in question is right around $97.40, plotted as a yellow line on both stock charts. Notice that's also the upper boundary of the gap left behind in January, begging to be closed now. * Not only would a move to fill in that gap possibly start a self-fueling selloff, it could lead the purple 50-day moving average line all the way below the green 200-day line. That's a sell signal in and of itself. * The last bastion of hope in the event of should the support at $97.40 snap is the 61.8% Fibonacci line around $92.64.As of this writing, James Brumley held no position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Deeply Discounted Energy Stocks to Buy * 7 Stocks to Buy In a Flat Market * 10 Stocks to Buy to Ride China's Emerging Wealth The post 3 Big Stock Charts for Thursday: Xilinx, Norfolk Southern and Iqvia Holdings appeared first on InvestorPlace.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
Picture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.